ReviewModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2021
Breast cancer with neuroendocrine differentiation: an update based on the latest WHO classification.
Review in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review.Frontiers in medicine · 2022Pooled it
- Human Meningiomas Reveal No Evidence of Neuroendocrine Differentiation.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Article
- Invasive Solid Papillary Carcinoma of the Breast Initially Diagnosed as Invasive Ductal Carcinoma: A Case Report.Surgical case reports · 2026Article
- Primary large cell neuroendocrine carcinoma of the breast with metastasis in the lymph nodes: a case report and literature review.Frontiers in oncology · 2026Article
- Oligometastatic Breast Cancer With Cutaneous Involvement and Paraneoplastic Hypercalcemia in a Young Woman.Cureus · 2025Article
- Emerging Breast Cancer Subpopulations: Functional Heterogeneity Beyond the Classical Subtypes.International journal of molecular sciences · 2025Review
- Primary neuroendocrine tumors of the breast according to the WHO 2019 classification; real life experiences of rare tumor types of the breast.The oncologist · 2025Article
- Case Report: Neuroendocrine carcinoma of the breast: a review of the literature and illustration of six cases.Frontiers in medicine · 2025Article
- S6K1 is a Targetable Vulnerability in Tumors Exhibiting Plasticity and Therapy Resistance.International journal of biological sciences · 2025Article
- Prognostic prediction for HER2-low breast cancer patients using a novel machine learning model.BMC cancer · 2024Article
- Changes in immunophenotypes after neoadjuvant endocrine therapy for prostate cancer and their clinical significance.Heliyon · 2024Article
- Neuroendocrine neoplasms of the breast: a review of literature.Virchows Archiv : an international journal of pathology · 2024Review
- CDK4/6 and aromatase inhibitors as first-line treatment in metastatic high-grade neuroendocrine carcinoma of the breast: A case report.Clinical case reports · 2024Article
- Neuroendocrine Breast Carcinoma: Interesting Images of an Underdiagnosed Entity.Diagnostics (Basel, Switzerland) · 2024Article
- Decoding the basis of histological variation in human cancer.Nature reviews. Cancer · 2024Review
- [Neuroendocrine expression markers in triple-negative, luminal-A, luminal-B and HER2neu breast cancer].Revista medica del Instituto Mexicano del Seguro Social · 2024Observational
- Comparison of clinical characteristics and outcomes in primary neuroendocrine breast carcinoma versus invasive ductal carcinoma.Frontiers in oncology · 2024Article
- Neuroendocrine breast carcinoma.Autopsy & case reports · 2024Article
- Clinicopathological Characteristics and Prognostic Profiles of Breast Carcinoma with Neuroendocrine Features.Life (Basel, Switzerland) · 2023Article
- Primary neuroendocrine breast cancer-an unusual occurrence.Ecancermedicalscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancers with neuroendocrine (NE) differentiation are very heterogeneous, comprising broadly cancers that are morphologically similar to NE tumors (NET) of other anatomic sites, infiltrating breast carcinomas, no special type (IBC-NST) and other special subtypes with NE morphology and/or NE markers expression. Depending on the classification schemes, they are variably included into "NE breast cancers". The latest WHO classification harmonized NE breast cancers with NE neoplasms (NEN) of other organ systems, defined NEN into well-differentiated NET (low Nottingham grade) and poorly-differentiated NE carcinoma (NEC) (high Nottingham grade). Other IBC with NE differentiation are diagnosed based on solely the non-NEN component. Due to the changes in diagnostic criteria, variable results were obtained in the previous studies on NE breast cancers. Hence, the clinical value of NE differentiation in breast cancers is not well investigated and understood. In this review, the current understanding in the pathogenesis, clinical, prognostic, immunhistochemical, and molecular features of "NE breast cancers" is summarized. Controversial issues in their diagnosis and classification are also discussed.
Indexed as
Identifiers
33531618What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.